Formulation of inactivated influenza vaccines for providing effective cross-protection by intranasal vaccination in mice.

[1]  T. Nagamine,et al.  Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit. , 1992, Journal of immunology.

[2]  T. Nagamine,et al.  Cross‐protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules , 1991, European journal of immunology.

[3]  T. Nagamine,et al.  Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza. , 1990, Vaccine.

[4]  I. Wilson,et al.  Structural basis of immune recognition of influenza virus hemagglutinin. , 1990, Annual review of immunology.

[5]  T. Nagamine,et al.  Protection against influenza virus infection by vaccine inoculated intranasally with cholera toxin B subunit. , 1988, Vaccine.

[6]  W. Fitch,et al.  Influenza B virus evolution: co-circulating lineages and comparison of evolutionary pattern with those of influenza A and C viruses. , 1988, Virology.

[7]  J. Robertson.  Sequence analysis of the haemagglutinin of A/Taiwan/1/86, a new variant of human influenza A(H1N1) virus. , 1987, The Journal of general virology.

[8]  N. Cox,et al.  The antigenicity and evolution of influenza H1 haemagglutinin, from 1950-1957 and 1977-1983: two pathways from one gene. , 1986, Virology.

[9]  F. Liew,et al.  Cross‐protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivity , 1984, European journal of immunology.

[10]  N. Cox,et al.  Antigenic drift in influenza virus H3 hemagglutinin from 1968 to 1980: multiple evolutionary pathways and sequential amino acid changes at key antigenic sites , 1983, Journal of virology.

[11]  B. Murphy,et al.  Secretory immunological response after intranasal inactivated influenza A virus vaccinations: evidence for immunoglobulin A memory , 1983, Infection and immunity.

[12]  J. Oxford,et al.  Quantitative analysis of the protein composition of influenza A and B viruses using high resolution SDS polyacrylamide gels. , 1981, Journal of biological standardization.

[13]  J. Holmgren.  Actions of cholera toxin and the prevention and treatment of cholera , 1981, Nature.

[14]  S. Fields,et al.  Nucleotide sequence of the haemagglutinin gene of a human influenza virus H1 subtype , 1981, Nature.

[15]  Christine Miller,et al.  ASSESSMENT OF INACTIVATED INFLUENZA-A VACCINE AFTER THREE OUTBREAKS OF INFLUENZA A AT CHRIST'S HOSPITAL , 1979, The Lancet.

[16]  F. Ennis,et al.  Review of existing vaccines for influenza. , 1978, American journal of clinical pathology.

[17]  M. Ui,et al.  An ultrasensitive method for the simultaneous determination of cyclic AMP and cyclic GMP in small-volume samples from blood and tissue. , 1977, Biochemical medicine.

[18]  Anthony C. Allison,et al.  ANTIBODY RESPONSES TO ANTIGENIC DETERMINANTS OF INFLUENZA VIRUS HEMAGGLUTININ , 1974, The Journal of experimental medicine.

[19]  R. Ganguly,et al.  Immunity to infections on secretory surfaces. , 1974, The Journal of infectious diseases.

[20]  J. Hierholzer,et al.  Standardized viral hemagglutination and hemagglutination-inhibition tests. I. Standardization of erythrocyte suspensions. , 1969, Applied microbiology.

[21]  R. Webster,et al.  Disquisitions of Original Antigenic Sin. I. Evidence in man. , 1966, The Journal of experimental medicine.

[22]  R. Webster,et al.  COMPARISONS OF SEROLOGIC AND FEBRILE RESPONSES IN HUMANS TO VACCINATION WITH INFLUENZA A VIRUSES OR THEIR HEMAGGLUTININS. , 1964, The Journal of laboratory and clinical medicine.